Evidence map›Paper›PMID 40166069›Full record

ArticleFrontiers in medicine2025

Molecular response of a patient with e19a2-positive chronic myeloid leukemia to flumatinib: a case report and literature review.

Yaqing Feng, Hongjin Wang, Lidong Zhang, Jinying Gong, Xi Liu, Caiqin Mu, Jun Qiao, Haitao Meng, Yanfang Zhang

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Uncommon phenotypes ofHaematologica · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaqing Feng *Department of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.
Hongjin Wang *Clinical Research Center, The Third People's Hospital of Datong, Datong, Shanxi, China.
Lidong ZhangDepartment of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.
Jinying GongState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Xi LiuDepartment of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.
Caiqin MuDepartment of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.
Jun QiaoDepartment of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.
Haitao MengDepartment of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.
Yanfang ZhangDepartment of Hematology, The Third People's Hospital of Datong, Datong, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Chronic myeloid leukemia (CML) is a malignancy driven by the Methods: We report a case of a 28-year-old female with e19a2-positive CML. The patient exhibited poor response and tolerance to dasatinib. After 6 months, she achieved partial cytogenetic response (PCyR) but developed grade 3 pleural effusion. Following treatment discontinuation and prednisone therapy, the patient continued dasatinib (80 mg/d). At 12 months, the patient achieved complete cytogenetic response (CCyR), but Conclusion: Flumatinib demonstrated excellent deep molecular response and good tolerability in e19a2-positive CML patients, suggesting that it may be one of the preferred treatment options for such patients.

Indexed as

chronic myeloid leukemiae19a2 transcriptflumatinibmolecular responsesecond-generation tyrosine kinase inhibitor

Identifiers

PMID40166069
PMCPMC11955632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.